AU
UK
CA
US
IND
NZ
Last update at 2026-06-15T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Undervalued Biotech Stocks With Breakout Potential
Fri 19 Jul 24, 12:00 AMThe 3 Most Undervalued Biotech Stocks to Buy in July 2024
Fri 12 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Income before tax | -27.33300M | - |
| Minority interest | 1.59M | - |
| Net income | -25.73800M | - |
| Selling general administrative | 3.47M | - |
| Selling and marketing expenses | - | - |
| Gross profit | - | - |
| Reconciled depreciation | - | - |
| Ebit | -29.63127M | -46.91400M |
| Ebitda | -27.16200M | - |
| Depreciation and amortization | - | - |
| Non operating income net other | - | - |
| Operating income | -27.16200M | - |
| Other operating expenses | - | - |
| Interest expense | - | - |
| Tax provision | - | - |
| Interest income | 0.00057M | - |
| Net interest income | 0.00057M | - |
| Extraordinary items | - | - |
| Non recurring | - | - |
| Other items | - | - |
| Income tax expense | - | - |
| Total revenue | 0.00000M | - |
| Total operating expenses | 27.16M | - |
| Cost of revenue | - | - |
| Total other income expense net | -0.17100M | - |
| Discontinued operations | - | - |
| Net income from continuing ops | -27.33300M | - |
| Net income applicable to common shares | -35.33454M | -46.91400M |
| Preferred stock and other adjustments | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 100.84M | 141.51M | 4.72M |
| Intangible assets | - | - | - |
| Earning assets | - | - | - |
| Other current assets | 1.04M | 0.02M | 0.42M |
| Total liab | 21.29M | 14.82M | 12.54M |
| Total stockholder equity | 59.33M | -32.05600M | -7.81900M |
| Deferred long term liab | - | 3.49M | - |
| Other current liab | 17.55M | 10.39M | 0.03M |
| Common stock | 0.00400M | - | - |
| Capital stock | 0.00400M | 141.37M | 139.38M |
| Retained earnings | -103.49400M | -32.05600M | -7.81900M |
| Other liab | - | - | - |
| Good will | - | - | - |
| Other assets | - | 141.47M | - |
| Cash | 99.81M | 0.01M | 4.72M |
| Cash and equivalents | - | - | - |
| Total current liabilities | 20.30M | 14.82M | 0.04M |
| Current deferred revenue | - | - | - |
| Net debt | -99.80600M | -0.01379M | - |
| Short term debt | - | - | - |
| Short long term debt | - | 0.36M | - |
| Short long term debt total | - | - | - |
| Other stockholder equity | 162.82M | - | - |
| Property plant equipment | - | - | - |
| Total current assets | 100.84M | 0.03M | 4.72M |
| Long term investments | - | - | - |
| Net tangible assets | - | -32.05600M | -7.81900M |
| Short term investments | - | - | - |
| Net receivables | - | - | - |
| Long term debt | - | - | - |
| Inventory | - | - | - |
| Accounts payable | 2.75M | 4.43M | 0.00700M |
| Total permanent equity | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - |
| Accumulated other comprehensive income | - | - | - |
| Additional paid in capital | - | - | - |
| Common stock total equity | - | - | - |
| Preferred stock total equity | - | - | - |
| Retained earnings total equity | - | - | - |
| Treasury stock | - | - | - |
| Accumulated amortization | - | - | - |
| Non currrent assets other | - | 3.49M | 139.40M |
| Deferred long term asset charges | - | - | - |
| Non current assets total | 0.00000M | 3.49M | 139.40M |
| Capital lease obligations | - | - | - |
| Long term debt total | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Investments | -12.00000M | - |
| Change to liabilities | 4.09M | 0.23M |
| Total cashflows from investing activities | -13.09091M | -30.00000M |
| Net borrowings | 8.29M | 8.29M |
| Total cash from financing activities | 16.11M | 60.00M |
| Change to operating activities | -0.22800M | -0.22800M |
| Net income | -28.07782M | -46.91400M |
| Change in cash | 1.71M | 28.32M |
| Begin period cash flow | 0.00000M | - |
| End period cash flow | 1.57M | - |
| Total cash from operating activities | -1.31127M | -1.68000M |
| Issuance of capital stock | 10.00M | - |
| Depreciation | - | - |
| Other cashflows from investing activities | - | - |
| Dividends paid | - | - |
| Change to inventory | - | - |
| Change to account receivables | - | - |
| Sale purchase of stock | - | - |
| Other cashflows from financing activities | -3.08836M | -3.08836M |
| Change to netincome | 22.90M | 45.00M |
| Capital expenditures | 12.00M | 0.00000M |
| Change receivables | - | - |
| Cash flows other operating | - | - |
| Exchange rate changes | - | - |
| Cash and cash equivalents changes | - | - |
| Change in working capital | 3.54M | - |
| Stock based compensation | 0.33M | - |
| Other non cash items | 22.23M | - |
| Free cash flow | -13.20200M | - |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| ZURA Zura Bio Limited Class A Ordinary Shares |
-0.02 0.54% | 3.68 | 7.87 | - | - | 2.47 | -2.3439 | |
| NVO Novo Nordisk A/S |
0.04 0.09% | 43.92 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.40 0.91% | 44.40 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.54 1.24% | 450.46 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.84 0.46% | 614.98 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
1489 W. Warm Springs Road, Henderson, NV, United States, 89014
| Name | Title | Year Born |
|---|---|---|
| Dr. Someit Sidhu M.D. | Founder & Non-Independent Director | 1990 |
| Mr. Verender S. Badial | Chief Financial Officer | 1973 |
| Dr. Michael D. Howell Ph.D. | Chief Scientific Officer | 1977 |
| Ms. Kimberly Ann Davis | Chief Legal Officer & Secretary | 1968 |
| Mr. Robert Lisicki | President, CEO & COO | 1968 |
| Dr. Gary Whale Ph.D. | Chief Technology Officer | 1974 |
| Ms. Theresa Lowry | Chief Human Resources Officer | 1974 |
| Mr. David Brady | Head of Business Development | NA |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development | 1973 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...